印度非专利药物制造商Natco在FDA批准糖尿病药物后,在监管更新和利润增加的情况下,获得11%的收益。 Indian generic drug maker Natco gains 11% after FDA approval for diabetes drug, amid regulatory updates and profit rise.

2026年2月16日, 印度包括Natco、Zydus、Piramal Pharma和Alkem Laboratories在内的印度保健库存因监管更新引起投资者兴趣。 On February 16, 2026, Indian healthcare stocks including Natco, Zydus, Piramal Pharma, and Alkem Laboratories drew investor interest due to regulatory updates. Natco Pharma在获得CDSCO批准后,生产并销售一种用于2型糖尿病的普通硫酸硫化物注射,并计划于2026年3月发射后,获得了11%以上的收益。 Natco Pharma gained over 11% after receiving CDSCO approval to manufacture and market a generic Semaglutide injection for type 2 diabetes, with a planned March 2026 launch. 该公司报告说,在Q3FY26中,净利润增长了13.9%,达到151.5克郎。 The company reported a 13.9% rise in net profit to ₹151.5 crore in Q3FY26. Zydus获得了12%的乳酸铵乳霜最终FDA批准，并回应了其Digwal工厂的四项FDA观察，这些观察被归类为自愿行动。 Zydus received final FDA approval for Ammonium Lactate Cream, 12%, and addressed four FDA observations at its Digwal plant, classified as voluntary action indicated. Natco还面临林业发展局对其Chennai API单位发出的VAI通知,要求采取纠正行动。 Natco also faced a VAI notice from the FDA over its Chennai API unit, requiring corrective actions.